Key result
Elevated NT-proBNP is linked to ~160% higher risk of ICU admission or death in COVID-19.
Why the study?
Data regarding the combined prognostic role of biomarkers and risk scores in relation to atherosclerotic cardiovascular disease history in COVID-19 patients were lacking.
Do elevated cardiac biomarkers (NT-pro BNP and troponin) predict ICU admission and death in hospitalized patients with mild to moderate COVID-19?
Cohort (n=1,066)
No
Do elevated cardiac biomarkers (NT-pro BNP and troponin) predict ICU admission and death in hospitalized patients with mild to moderate COVID-19?
Answers are grounded in this paper and cite their sources.
Elevated NT-pro BNP and troponin levels upon admission are strong independent predictors of ICU admission and mortality in patients with mild-to-moderate COVID-19, particularly those with a history of ASCVD.
BACKGROUND: Data regarding the combined prognostic role of biomarkers and risk scores in relation with the history of atherosclerotic cardiovascular disease (ASCVD) in COVID-19 patients are lacking. METHODS: The aim of this observational cohort study was to evaluate the combined prognostic value of N-terminal pro B-type natriuretic peptide (NT-pro BNP), troponin and risk scores in relation with ASCVD history in hospitalized COVID-19 patients. The primary composite endpoint was Intensive Care Unit (ICU) admission and death. RESULTS: From April 2020 to June 2022, 1066 consecutive COVID-19 patients with available biomarkers upon admission were included. During a median follow-up period of 12 days, 176 patients (16.5%) died. Independent predictors of ICU admission and death in patients with ASCVD were NT-pro BNP (HR 2.63; 95% CI, 1.65-4.18) and troponin (HR 1.51; 95% CI, 1.13-2.03). In patients without ASCVD, only NT-pro BNP was predictive for the primary endpoint (HR 1.66; 95% CI, 1.10-2.53). This remained significant after adjustment for other relevant covariates (HR 3.54; 95% CI, 1.98-6.33) in patients with ASCVD and in patients without ASCVD (HR 1.82; 95% CI, 1.02-3.26). CONCLUSIONS: These data showed the combined prognostic accuracy of NT-pro BNP and troponin in relation with ASCVD history for ICU admission and death in COVID-19 patients.
No takes yet. Share an insight, caveat, or question.
Lionte et al. (2022) conducted a cohort in COVID-19 (n=1,066). Elevated NT-pro BNP and troponin vs. Lower levels of NT-pro BNP and troponin was evaluated on Composite of Intensive Care Unit (ICU) admission and in-hospital death (HR 2.63, 95% CI 1.65-4.18). Elevated NT-pro BNP was an independent predictor of ICU admission and death in COVID-19 patients with a history of ASCVD (HR 2.63) and without ASCVD (HR 1.66).
Synapse has enriched 10 related papers. Consider them for comparative context: